PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.

Mirati raises $300m as its chief exec departs. What’s not to like?

Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.

EQRX had once hoped to disrupt cosy US cancer drug pricing arrangements, but when that model failed the group found that cash was its best asset.

However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.

Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.